Table 2.
Surgical and pathology findings
| Variable | CA-SAP group (n = 49) | SAP group (n = 49) |
|---|---|---|
| Surgical technology | ||
| Open | 1 (2.0) | 0 (0.0) |
| Laparoscopic | 45 (91.8) | 48 (98.0) |
| Robotic | 3 (6.1) | 1 (2.0) |
| Type of gastrectomy | ||
| Total | 39 (79.6) | 44 (89.8) |
| Distal | 9 (18.4) | 5 (10.2) |
| Proximal | 1 (2.0) | 0 (0.0) |
| Blood loss, mL | 35 (30–50) | 30 (30–50) |
| No. of lymph node metastasis | 1 (0–7) | 1 (0–7) |
| No. of lymph node harvested | 40 (29–55) | 40 (34–54) |
| Lymphovascular invasion | ||
| No | 25 (51.0) | 28 (57.1) |
| Yes | 24 (49.0) | 21 (42.9) |
| Neural invasion | ||
| No | 21 (42.9) | 19 (38.8) |
| Yes | 28 (57.1) | 30 (61.2) |
| ypT stage | ||
| T0 | 8 (16.3) | 3 (6.1) |
| T1 | 4 (8.2) | 5 (10.2) |
| T2 | 5 (10.2) | 5 (10.2) |
| T3 | 23 (46.9) | 23 (46.9) |
| T4a | 9 (18.4) | 13 (26.5) |
| ypN stage | ||
| N0 | 18 (36.7) | 21 (42.9) |
| N1 | 12 (24.5) | 8 (16.3) |
| N2 | 7 (14.3) | 7 (14.3) |
| N3 | 12 (24.5) | 13 (26.5) |
| ypM stage | ||
| M0 | 49 (100.0) | 47 (95.9) |
| M1 | 0 (0.0) | 2 (4.1) |
| Pathological response | ||
| TRG 1a | 8 (16.3) | 3 (6.1) |
| TRG 1b | 9 (18.4) | 6 (12.2) |
| TRG 2 | 10 (20.4) | 21 (42.9) |
| TRG 3 | 22 (44.9) | 19 (38.8) |
Data are No. (%) or median (first quartile-third quartile [Q1–Q3]). Because of rounding, not all percentages add up to 100%.
CA-SAP camrelizumab, apatinib, nab-paclitaxel, and S-1, SAP nab-paclitaxel and S-1, TRG tumor regression grade.